Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 2c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Goldman: 'Our top picks include XYZ, KLAR, AFRM, and CHYM'
• Par Pacific Holdings (PARR) PT Raised to $80 at Mizuho
• PepsiCo (PEP) Misses Q2 EPS by 1c, Beats on Revenue